Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection
Unicycive Therapeutics announced its Q2 2026 financial results, reporting $61.4 million in cash and securities, expected to fund operations into 2027. The company's lead drug, oxylanthanum carbonate (OLC), received a Complete Response Letter from the FDA due to third-party manufacturing deficiencies, but the FDA …